ZyVersa Therapeutics, Inc. announced significant advancements regarding its Inflammasome ASC Inhibitor IC 100, with plans to position it as a complementary therapy alongside GLP-1 agonists for ...
New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four leading inflammasome experts and inventors of IC 100 from University of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results